Clinical trial
Trial of Screening for ALOA-IgG AtheroAbzyme Test Comparing Healthy,Asymptomatic Myocardial Ischemic and Acute Coronary Syndrome Patients
NCT01272986 is registered in ClinicalTrials.gov with Omicron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Trial of Screening for ALOA-IgG AtheroAbzyme Test Comparing Healthy,Asymptomatic Myocardial Ischemic and Acute Coronary Syndrome Patients
- Lead sponsor
- Omicron Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2011
- Completion date
- March 31, 2011
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.